Vaccinex Inc

Vaccinex, Inc. operates as a clinical-stage biotechnology company. It engages in the development of targeted bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The firm focuses on the development of Pepinemab for the treatment of non-small cell lung cancer, or NSCLC, osteosarcoma, melanoma, and Huntington’s disease. Its product pipeline includes the SEMA4D antibody platform and ActivMAb antibody discovery platform. The company was founded by Maurice Zauderer and Deepak Sahasrabudhe in 1997 and is headquartered in Rochester, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vaccinex, Inc. operates as a clinical-stage biotechnology company. It engages in the development of targeted bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The firm focuses on the development of Pepinemab for the treatment of non-small cell lung cancer, or NSCLC, osteosarcoma, melanoma, and Huntington’s disease. Its product pipeline includes the SEMA4D antibody platform and ActivMAb antibody discovery platform. The company was founded by Maurice Zauderer in April 2001 and is headquartered in Rochester, NY.

ROCHESTER, N.Y., March 09, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced that it has been selected for poster presentation related to the phase 1b segment of its KEYNOTE-B84 study of pepinemab in combination with KEYTRUDA (pembrolizumab) in patients with recurrent or metastatic head and neck cancer during the upcoming 2022 American Association for Cancer Research Meetings (2022 AACR), taking place from April 8th to April 13th in New Orleans via in person and virtual attendance.

Vaccinex, Inc. Announces Upcoming Presentation at the 2022 American Association for Cancer Research Meeting Updating the Phase 1b Segment of the KEYNOTE-B84 Study of Pepinemab in Combination with KEYTRUDA (pembrolizumab) in Patients with Recurrent or Meta

Poster Presentation: Combination immunotherapy and HTT-lowering in humanized HD mice, Wednesday, March 2, 2022 Poster Presentation: Combination immunotherapy and HTT-lowering in humanized HD mice, Wednesday, March 2, 2022

Vaccinex, Inc. to Present at CHDI's 17th Annual HD Therapeutics Conference Meeting

Eyenovia

loanDepot

MannKind

Oncternal Therapeutics Inc

Performant Financial

P3 Health Partners Inc

Pixelworks

Penny stocks to buy now according to insiders. The post 8 Penny Stocks To Buy Now According To Insiders In 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

8 Penny Stocks To Buy Now According To Insiders In 2022

Insiders are scooping up shares of these penny stocks in 2022. The post 5 Penny Stocks To Buy Now According To Insiders In 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Penny Stocks To Buy Now According To Insiders In 2022

The unemployment rate in the Eurozone dropped to a record low of 7% in December from a revised 7.1% level in the previous month, helping the STOXX Europe 600 Index record gains this morning. Investors, meanwhile, focused on some notable insider trades.

Vaccinex And 4 Other Penny Stocks Bought By Insiders

Participants include a syndicate of existing and new shareholders Contributes to total of $10.1 million in new equity financing for January, 2022

Vaccinex Announces $6.6 Million Private Placement

Vaccinex Inc shares are gaining after the Company reported interim response data in the Phase Ib segment of the KEYNOTE-B84 study.

Vaccinex Posts Two Complete Responses In Pepinemab Combo Trial In Head & Neck Cancer

Blue Star Foods Corp

Ondas Holdings

Stran & Co

Penny stocks to buy under $5 right now. Are they worth the risk?

4 Hot Penny Stocks To Buy Under $5 Right Now

The stock price of Vaccinex Inc (NASDAQ: VCNX) increased by over 20% pre-market today. This is why it happened.

Vaccinex Stock (VCNX): Why The Price Surged Up Today

ROCHESTER, N.Y., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX, Vaccinex, the Company), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of semaphorin 4D (SEMA4D), today reported positive interim response data in the Phase Ib segment of the KEYNOTE-B84 study of Vaccinex's pepinemab in combination with Merck's (known as MSD outside of the United States and Canada) anti-PD-1 therapy KEYTRUDA (pembrolizumab) in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).

Vaccinex Reports Two Complete Responses in First Three Patients Enrolled in the Phase 1b/2 KEYNOTE-B84 Study of Pepinemab in Combination with KEYTRUDA (pembrolizumab) in Patients with Recurrent or Metastatic Head and Neck Cancer

Phase 1b segment evaluated safety and tolerability of the combination

Vaccinex Reports Phase Ib KEYNOTE B84 Combination Study of Keytruda® and Pepinemab in Patients with Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Passes Planned Interim Safety Analysis

In-person and virtual Presentation: November 10-14th, 2021 In-person and virtual Presentation: November 10-14th, 2021

Vaccinex, Inc. to Present at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting

Live Presentation: Thursday, Nov. 11, 2021 Live Presentation: Thursday, Nov. 11, 2021

Vaccinex, Inc. to Present at the Clinical Trials on Alzheimer's Disease (CTAD) Meeting

Enrollment underway in combination Phase 1b/2 study of pepinemab with KEYTRUDA® in Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Vaccinex Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Virtual Dates: November 18 th – 19 th , 2021

Vaccinex, Inc. to Present at the 12th Annual Jefferies London Healthcare Conference

Presentation to highlight expanded post-hoc subgroup analysis of the SIGNAL Phase 2 Huntington's Disease (HD) trial suggesting a cognitive benefit in patients with mildly advanced disease Presentation to highlight expanded post-hoc subgroup analysis of the SIGNAL Phase 2 Huntington's Disease (HD) trial suggesting a cognitive benefit in patients with mildly advanced disease

Vaccinex to Present at the Virtual Huntington's Study Group Meeting on November 4-6, 2021

ROCHESTER, N.Y., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology Company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, a potent biological mediator, today announced that Elizabeth Evans, PhD, Chief Operating Officer, is scheduled to present at the Oppenheimer & Co. Inc. Fall Healthcare Life Sciences and MedTech Summit.

Vaccinex to Present at the Oppenheimer & Co. Inc. Fall Healthcare Life Sciences and MedTech Summit

Patients are currently being screened and enrolled in two studies of pepinemab as monotherapy in Alzheimer's disease and in combination with KEYTRUDA® in Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Vaccinex Reports Second Quarter 2021 Financial Results and Provides Corporate Update

ROCHESTER, N.Y., June 30, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology Company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced that Elizabeth Evans, PhD, Chief Operating Officer and Senior Vice President, Discovery and Translational Medicine, will chair a Symposium and panel Q&A session and present a poster at the XV European Meeting on Glial Cells in Health and Disease, which is being held virtually from July 5 – 9, 2021.

Vaccinex to Chair Panel Q&A Session and Present Poster at the XV European Meeting on Glial Cells in Health and Disease

Vaccinex Inc (NASDAQ: VCNX) has activated first clinical sites to screen and enroll patients in its Phase 1/2 study evaluating pepinemab as a single agent in Alzheimer's disease (AD) and in its phase 2 study in combination with Merck & Co Inc's (NYSE: MRK) Keytruda (pembrolizumab) for advanced, recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The Alzheimer's proof-of-concept study is expected to enroll at least 40 patients with key efficacy endpoints that include cognition and brain imaging measures.

Vaccinex Initiates Pepinemab Trials for Alzheimer's, Head & Neck Cancer

Company plans to activate at least 13 clinical sites for Alzheimer's study and 18 clinical sites for head and neck cancer across the United States Company plans to activate at least 13 clinical sites for Alzheimer's study and 18 clinical sites for head and neck cancer across the United States

Vaccinex Announces Activation of Clinical Sites to Enroll Patients in Studies of Pepinemab as Single Agent in Alzheimer's Disease and in Combination with KEYTRUDA® in Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Initiated Phase 2 study of pepinemab in combination with KEYTRUDA® in advanced, recurrent or metastatic head and neck cancer

Vaccinex Reports First Quarter 2021 Financial Results and Provides Corporate Update

CLASSICAL-Lung study evaluated pepinemab in combination with the checkpoint inhibitor BAVENCIO® for the treatment of non-small cell lung cancer CLASSICAL-Lung study evaluated pepinemab in combination with the checkpoint inhibitor BAVENCIO® for the treatment of non-small cell lung cancer

Vaccinex Announces Publication of Results from CLASSICAL-Lung Phase 1b/2 Clinical Trial in Non-Small Cell Lung Cancer in the Peer-Reviewed Journal Clinical Cancer Research

Reported top-line results from Phase 2 SIGNAL study that indicates potential cognitive benefit of pepinemab in neurodegenerative disease. New Alzheimer's study expected to begin enrollment in Q2

Vaccinex Reports Fourth Quarter 2020 Financial Results and Provides Corporate Update

The stock price of Vaccinex, Inc. (Nasdaq: VCNX) increased over 18% during intraday trading today. This is why it happened.

News for Vaccinex Inc Stock (VCNX)